Class 530/391.1 - Monoclonal or polyclonal antibody or immunoglobulin or fragment thereof that is conjugated or adsorbed (e.g., adsorbed to a solid support, etc.)

Subclass of Class 530 - Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Definition: Subject matter involving a monoclonal or polyclonal antibody
No. of patents: 873
Last issue date: 05/29/2012

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8188239	Multivalent carriers of bi-specific antibodies Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the associ...	05/29/2012
8153768	Calicheamicin derivative-carrier conjugates Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjug...	04/10/2012
8053564	Cross-linked antibodies The present invention provides a compound consisting essentially of the following elements: one or more reactive groups; and two or more cross-linked antibodies or fragments thereof; characterised in that the or each reactive group is suitable for attaching an effec...	11/08/2011
8003767	Sulfonated [8,9]benzophenoxazine dyes and the use of their labelled conjugates Fluorescent, sulfonated 3,7-diamino-[8,9]benzophenoxazine dyes are provided that are especially useful for labelling biopolymers and other substrates. The dye-labelled conjugates can be used in a variety of contexts, including cell surface assays employing intact, l...	08/23/2011
7951920	Conjugate of an antibody against CCR5 and an antifusogenic peptide The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the a...	05/31/2011
7951921	Multivalent carriers of bi-specific antibodies Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the associ...	05/31/2011
7868143	Microparticle with cd28-specific monoclonal antibodies The invention relates to microparticles with a support structure and CD28-specific superagonistic monoclonal antibodies (mAbs) bonded to the support structure or a compound mimicking the above. ...	01/11/2011
7632927	Radioimmunoconjugates for targeted alpha therapy A radioimmunoconjugate for targeted alpha therapy comprises an alpha-emitter (e.g. Bi-213) linked to the monoclonal antibody C595. This radioimmunoconjugate is widely applicable in cancer therapy and is particularly efficient for treatment of pancreatic and prostate...	12/15/2009
7592431	Biodegradable T-cell Activation device A biodegradable device for activating T-cells includes a biodegradable support and a binder attached to the biodegradable support, the binder having reactivity to one or more agents capable of binding to a T-cell surface antigen. ...	09/22/2009
7442777	Cytotoxicity mediation of cells evidencing surface expression of CD63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ...	10/28/2008
7442778	Modified Fc molecules The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one pept...	10/28/2008
7442497	Methods of determining chronic hepatitis C infection Methods for determining chronic hepatitis C infection are provided by the present invention. The methods generally involve determining the optical density of fluid samples which have tested positive for hepatitis C infection using an antibody-based assay. The optica...	10/28/2008
7438908	Anti-human tenascin monoclonal antibody A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the indus...	10/21/2008
7435592	Compositions for allogeneic cell therapy A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune m...	10/14/2008
7427668	Antibodies binding the TNF related protein, TNF-Y Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.	09/23/2008
7425620	FcγRIIB-specific antibodies and methods of use thereof The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods ...	09/16/2008
7425619	FcγRIIB specific antibodies and methods of use thereof The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods ...	09/16/2008
7423125	Antibodies to VEGF-C Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that...	09/09/2008
7420039	Individualized anti-cancer antibodies The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production o...	09/02/2008
7411046	Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ...	08/12/2008
7402431	T-cell therapy formulation Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation...	07/22/2008
7399644	Immunoassay, reagent for immunoassay, and production method of the same An assay method for determining presence of a target antibody or antigen in a specimen qualitatively or quantitatively by mixing the specimen with an antigen or antibody immunologically reactive with the target antibody or antigen, and assaying the level of the immu...	07/15/2008
7399846	Libraries of oligomers labeled with different tags A method of making a set of labelled compounds by the use of a preferably particulate support, comprises dividing the support into lots, performing a different chemical reaction on each lot of the support, e.g. to couple a chemical moiety to that lot of the support,...	07/15/2008
7399835	Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ...	07/15/2008
7393531	Cytotoxicity mediation of cells evidencing surface expression of MCSP This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ...	07/01/2008
7390489	Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria...	06/24/2008
7387772	Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ...	06/17/2008
7378091	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity ...	05/27/2008
7361343	Cytotoxicity mediation of cells evidencing surface expression of CD63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ...	04/22/2008
7361347	Cytotoxic CD44 antibody immunoconjugates The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy. ...	04/22/2008
7361342	Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ...	04/22/2008
7358096	Immobilisation of proteins The immobilization of proteins at solid surfaces facilitated by incorporation of a polypeptide segment which is capable of adopting a folded structure is described. Materials comprising proteins so immobilized and uses thereof are also described. ...	04/15/2008
7358094	Sensor system for saccharides An analytical system for detecting a saccharide is provided. The analytical system includes a saccharide sensor attached to a solid substrate and having the formula: Where Z is selected from the group consisting of hydrogen...	04/15/2008
7357927	Death domain containing receptors The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 prote...	04/15/2008
7355017	Blood group antigen fusion polypeptides and methods of use thereof The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection. ...	04/08/2008
7351591	Surface modification of metals for biomolecule detection using surface enhanced Raman scattering (SERS) The present invention is based on the discovery that the methods described herein for the production of metallic colloids result in colloids exhibiting increased signal enhancement and reproducibility for the SERS detection of biomolecules. Thus, using the methods o...	04/01/2008
7351797	Labeled peptides, and processes and intermediates useful for their preparation The invention provides intermediates and methods that allow for site-specific modification of peptides after synthesis. Accordingly, functional molecules can be selectively linked to a peptide to provide a peptide conjugate having altered biological, chemical, or ph...	04/01/2008
7351862	Alpha, omega-difunctional aldaramides Alpha, omega-difunctional aldaramides, in particular diaminoaldaramides, dihydroxyaldaramides, bis(alkoxycarbonylalkyl)aldaramides, and bis(carboxyalkyl)aldaramides, and processes for preparing the aldaramides are provided. ...	04/01/2008
7348413	Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ...	03/25/2008
7339034	PRO1305 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ...	03/04/2008

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Class 530/391.1 - Monoclonal or polyclonal antibody or immunoglobulin or fragment thereof that is conjugated or adsorbed (e.g., adsorbed to a solid support, etc.)